The compositions and methods described herein are directed to treating solid tumors using CAR T therapy. For example, the compositions include CAR T cells comprising an extracellular domain that binds OR2I1P, LY6G6D, LRRC15, LY6K, GCC, GFRA4, F2RL2, QRFPR, IQGAP3, SIGLEC15, HAVCR1, PSG9, KISS1R, PRAME, HCN4, DPEP3, TMEM270, HER2, SLC7A3, SPRR2F, SLC45A2, CHRM1, CHRNA2, STEAP1B, FCRL2, Luteinizing hormone receptor, EDB, or CLDN18.2.

Disclosed are senescent cell-associated antigen-binding domain and related antibodies and related chimeric antigen receptors. In addition, disclosed are DPP4-binding domains and related antibodies and related chimeric antigen receptors. Also disclosed are methods for treating, preventing or alleviating senescence-related diseases or disorders. Methods for depleting and/or killing senescent cells are also disclosed.

Antibodies and compositions against Claudin 6 and uses thereof are provided.

Provided herein are novel anti-LHR chimeric antigen receptor (CAR), cells or compositions comprising the same, vector or plasmid encoding anti-LHR CAR, and methods for producing the same, or using the same for detecting or treating ovarian cancer or prostate cancer. Also provided herein are anti-LHR antibody, compositions comprising the same, nucleic acid sequence encoding the same, and a kit for detecting LHR.

The present invention discloses administering pharmaceutical compositions in combination, one of which is a pharmaceutical composition containing a tolinapant drug, and the other of which is a pharmaceutical composition containing an immune cell modified to express a chimeric antigen receptor or a recombinant T-cell receptor.

The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.

Provided herein are chimeric antigen receptors (CARs) that include a) an antigen binding domain specific for an antigen, b) a spacer, c) a transmembrane domain, and d) an intracellular signaling domain, wherein the spacer consists of 1, 2 or 3 C2-set Ig-like domain(s) e.g., C2-set Ig-like domains of the sialic acid binding Ig-like lectin (Siglec) family. Also provided herein are compositions including a) an immune cell expressing a CAR, wherein the CAR is specific for a tag and b) a tagged polypeptide.

The present invention relates to a pharmaceutical composition for the prevention or treatment of immune disorders and inflammatory diseases, comprising stem cells that are generated by culturing stem cells expressing Nucleotide-binding Oligomerization Domain protein 2 (NOD2) or a culture thereof. More particularly, the present invention relates to a method for suppressing immune responses or inflammatory responses of a subject, comprising the step of administering the pharmaceutical composition, the stem cells or culture thereof to the subject, a method for preparing an immunosuppressive drug or an anti-inflammatory drug using the stem cells or culture thereof, a graft comprising stem cells expressing NOD2, a method for preparing the graft, a composite comprising stem cells expressing NOD2, and a culture generated by culturing the NOD2-expressing stem cells.

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having -folate receptor (FR) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.

Disclosed herein are modified NK cells, compositions comprising modified NK cells, and methods for treating a tumor or hyperproliferative disease in a subject. In some embodiments, the modified NK cells include NK cells including a heterologous nucleic acid molecule encoding a CD16 protein comprising a valine at amino acid position 158 (CD16-V158), a heterologous nucleic acid molecule encoding a CCR7 protein, or both. In some embodiments, methods include treating a subject with a tumor by administering a composition comprising an anti-cancer monoclonal antibody and administering a composition comprising the modified NK cells to the subject. Also disclosed are methods of making modified NK cells by obtaining a population of NK cells from a subject and transfecting the population of NK cells with a heterologous nucleic acid molecule encoding CD16-V158, a heterologous nucleic acid molecule encoding a CCR7 protein, or both.